{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:26:33Z","timestamp":1785540393931,"version":"3.56.0"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Biogen Netherlands B.V"},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Europharm Limited"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p> Our aim was to estimate and compare the prevalence of adverse pregnancy outcomes among pregnant women with multiple sclerosis (MS) exposed to interferon beta (IFNB) and among women with MS unexposed to any MS disease-modifying drug (MSDMD). <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> This cohort study used Finnish (1996\u20132014) and Swedish (2005\u20132014) national register data. Women with MS having IFNB dispensed 6\u2009months before or during pregnancy as the only medication were considered as IFNB exposed (only IFNB-exposed), whereas women with MS unexposed to any MSDMD were considered unexposed (MSDMD-unexposed). Prevalence was described and compared using log-binomial or logistic regression and adjusted for potential confounders including maternal age and comorbidity. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Among 2831 pregnancies, 2.2% of the only IFNB-exposed and 4.0% of the MSDMD-unexposed women had serious adverse pregnancy outcomes [elective termination of pregnancy due to foetal anomaly (TOPFA), major congenital anomaly (MCA) in live, or stillbirth]. After adjustments, the prevalence of serious adverse pregnancy outcomes was lower among the only IFNB-exposed compared with the MSDMD-unexposed [relative risk 0.55, 95% confidence interval (CI) 0.31\u20130.96]. The prevalence of individual outcomes, including MCA, spontaneous abortions, and stillbirths was not increased with IFNB exposure. Women with MS exposed to IFNB appeared more likely to terminate their pregnancy for reasons other than foetal anomaly, compared with MSDMD-unexposed pregnant MS patients (odds ratio 1.71, 95% CI 1.06\u20132.78). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> In this large cohort study, no increase in the prevalence of adverse pregnancy outcomes was observed in women with MS exposed to IFNB compared with MS patients unexposed to any MSDMDs. This study together with other evidence led to a change in the labels of the IFNB products in September 2019 in the European Union, and IFNB use today may be considered during pregnancy, if clinically needed. <\/jats:p><\/jats:sec>","DOI":"10.1177\/1756286420951072","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T05:09:16Z","timestamp":1602133756000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":29,"title":["Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7313-8532","authenticated-orcid":false,"given":"Katja Marja","family":"Hakkarainen","sequence":"first","affiliation":[{"name":"StatFinn & EPID Research, Pr\u00e4stg\u00e5rdsgatan 28, 431 44 M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Juuti","sequence":"additional","affiliation":[{"name":"StatFinn & EPID Research, Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Burkill","sequence":"additional","affiliation":[{"name":"Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Geissb\u00fchler","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Evidence and Launch Excellence, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Sabid\u00f3","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrinel","family":"Popescu","sequence":"additional","affiliation":[{"name":"Biogen Idec Ltd, Maidenhead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiliana","family":"Suzart-Woischnik","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hillert","sequence":"additional","affiliation":[{"name":"Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Artama","sequence":"additional","affiliation":[{"name":"University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auli","family":"Verkkoniemi-Ahola","sequence":"additional","affiliation":[{"name":"Clinical Neurosciences, Neurology, University of Helsinki, Helsinki, Finland"},{"name":"Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"Department of Neurology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Meht\u00e4l\u00e4","sequence":"additional","affiliation":[{"name":"StatFinn & EPID Research, Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Bahmanyar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden"},{"name":"Centre for Psychiatry Research, Karolinska Institutet, Solna, Stockholm, Sweden"},{"name":"Stockholm Health Care Services, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden"},{"name":"School of Medical Sciences, Clinical Epidemiology and Biostatistics, \u00d6rebro University, Sweden"},{"name":"Department of Epidemiology and Public Health, University College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi","family":"Korhonen","sequence":"additional","affiliation":[{"name":"StatFinn & EPID Research, Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Wicklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Akbaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Borghesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evra","family":"K\u00f6f\u00fcnc\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Everage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avni","family":"Pandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milorad","family":"Todorovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Issard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Macklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Primatesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Weitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riho","family":"Klement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Vehkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Vattulainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Korjagina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Gyllensten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"bibr1-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1097\/JPN.0b013e31829d98c5"},{"key":"bibr2-1756286420951072","unstructured":"Biogen Netherlands B.V. Summary of product characteristics; AVONEX [Internet], 2019, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/avonex-epar-product-information_en.pdf (accessed 10 August 2020)."},{"key":"bibr3-1756286420951072","unstructured":"Bayer AG. Summary of product characteristics; Betaferon [Internet], 2019, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/betaferon-epar-product-information_en.pdf (accessed 10 August 2020)."},{"key":"bibr4-1756286420951072","unstructured":"Novartis Europharm Limited. Summary of product characteristics; Extavia [Internet], 2019, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/extavia-epar-product-information_en.pdf (accessed 10 August 2020)."},{"key":"bibr5-1756286420951072","unstructured":"Biogen Netherlands B.V. Summary of product characteristics; Plegridy [Internet], 2019, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/plegridy-epar-product-information_en.pdf (accessed 10 August 2020)."},{"key":"bibr6-1756286420951072","unstructured":"European Medicines Agency. Rebif [Internet], 2020, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rebif-epar-product-information_en.pdf (accessed 10 August 2020)."},{"key":"bibr7-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13536"},{"key":"bibr8-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517751049"},{"key":"bibr9-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.14"},{"key":"bibr10-1756286420951072","volume":"31","author":"Boneschi FM","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr11-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516634872"},{"key":"bibr12-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1177\/1756285612453192"},{"key":"bibr13-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308113"},{"key":"bibr14-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004536"},{"key":"bibr15-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510394610"},{"key":"bibr16-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181fd62bb"},{"key":"bibr17-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509106543"},{"key":"bibr18-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0909-4"},{"key":"bibr19-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182698c64"},{"key":"bibr20-1756286420951072","volume":"2016","author":"Alroughani R","year":"2016","journal-title":"Mult Scler Int"},{"key":"bibr21-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1311321"},{"key":"bibr22-1756286420951072","unstructured":"EPID Research. Pregnancy outcomes in multiple sclerosis populations exposed and unexposed to interferon \u03b2 \u2013 a register-based study in the Nordic countries [Internet], 2015, http:\/\/www.encepp.eu\/encepp\/openAttachment\/fullProtocol\/13164;jsessionid=OJ0xcA1W9KJ5YmoVOTxtrWJ0RzswVzoX4GPwRm6StJFFlMKeCAUh!-1357411575 (accessed 1 November 2019)."},{"key":"bibr23-1756286420951072","unstructured":"The National Institute for Health and Welfare. Care register for health care [Internet]. The National Institute for Health and Welfare (THL), Finland, 2016, http:\/\/thl.fi\/fi\/web\/thlfi-en\/statistics\/information-on-statistics\/register-descriptions\/care-register-for-health-care (accessed 10 December 2018)."},{"key":"bibr24-1756286420951072","unstructured":"The National Institute for Health and Welfare. Medical birth register [Internet]. The National Institute for Health and Welfare (THL), Finland, 2019, http:\/\/thl.fi\/en\/web\/thlfi-en\/statistics\/information-on-statistics\/register-descriptions\/newborns (accessed 10 December 2018)."},{"key":"bibr25-1756286420951072","doi-asserted-by":"publisher","DOI":"10.23979\/fypr.45059"},{"key":"bibr26-1756286420951072","unstructured":"The National Institute for Health and Welfare. Register of induced abortions - THL [Internet]. The National Institute for Health and Welfare (THL), Finland, 2015, http:\/\/thl.fi\/en\/web\/thlfi-en\/statistics\/information-on-statistics\/register-descriptions\/register-of-induced-abortions (accessed 10 December 2018)."},{"key":"bibr27-1756286420951072","unstructured":"The National Institute for Health and Welfare. Register of Congenital malformations - Quality description [Internet]. The National Institute for Health and Welfare (THL), Finland, 2015, http:\/\/thl.fi\/en\/web\/thlfi-en\/statistics\/information-on-statistics\/register-descriptions\/register-of-congenital-malformations (accessed 10 December 2018)."},{"key":"bibr28-1756286420951072","unstructured":"Kela. Statistics on reimbursement entitlements in respect of medicines [Internet], 2020, https:\/\/www.kela.fi\/en\/web\/en\/statistics-by-topic\/reimbursement-entitlements-in-respect-of-medicines (accessed 10 August 2020)."},{"key":"bibr29-1756286420951072","unstructured":"Kela. Statistics on reimbursements for prescription medicines [Internet], 2020, https:\/\/www.kela.fi\/web\/en\/statistics-by-topic\/reimbursements-for-prescription-medicines (accessed 10 August 2020)."},{"key":"bibr30-1756286420951072","unstructured":"Socialstyrelsen. The National Patient Register [Internet], 2019, https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/register-information\/the-national-patient-register\/ (accessed 10 August 2020)."},{"key":"bibr31-1756286420951072","unstructured":"Socialstyrelsen. The Swedish Medical Birth Register [Internet], 2019, https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/register-information\/the-swedish-medical-birth-register\/ (accessed 10 August 2020)."},{"key":"bibr32-1756286420951072","unstructured":"Socialstyrelsen. L\u00e4kemedelsregistret (in Swedish) [Internet], 2020, https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/alla-register\/lakemedelsregistret\/ (accessed 10 August 2020)."},{"key":"bibr33-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"bibr34-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12425"},{"key":"bibr35-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"bibr36-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000168905.97207.d0"},{"key":"bibr37-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512471880"},{"key":"bibr38-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000180575.77021.c4"},{"key":"bibr39-1756286420951072","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmp057"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286420951072","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756286420951072","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286420951072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T10:59:40Z","timestamp":1740999580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756286420951072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":39,"alternative-id":["10.1177\/1756286420951072"],"URL":"https:\/\/doi.org\/10.1177\/1756286420951072","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"1756286420951072"}}